News
Alnylam launches drug trial to treat rare disease
July 7, 2010 10:35 am | by Mass High Tech: The Journal of New England Technology | CommentsAlnylam Pharmaceuticals Inc. has launched a Phase 1 trial for a drug candidate targeting a rare disease known as ATTR. Investors and analysts are taking notice because it is one of just a handful of RNAi human trials ongoing.
Cancer deaths continue to drop
July 7, 2010 10:34 am | by EurekAlert | Comments(American Cancer Society) The continued drop in overall cancer mortality rates over the last 20 years has averted more than 767,000 cancer deaths according to a new report from the American Cancer Society.
Summary Information for: Implantable Miniature Telescope?
July 7, 2010 10:31 am | by U.S. Food & Drug Administration | CommentsLabeling, Approval Order, and Summary of Safety and Effectiveness for Implantable Miniature Telescope? (P050034).
510(k) Final Decisions - June 2010(2)
July 7, 2010 10:31 am | by U.S. Food & Drug Administration | CommentsPage Last Updated: 07/07/2010 Note: If you need help accessing information in different file formats, see Instructions for Downlo
510(k) Final Decisions - June 2010
July 7, 2010 10:30 am | CommentsPage Last Updated: 07/07/2010 Note: If you need help accessing information in different file formats, see Instructions for Downlo
Synageva gains orphan drug status for enzyme therapy
July 7, 2010 9:37 am | by Mass High Tech: The Journal of New England Technology | CommentsSynageva BioPharma Corp. announced today that the U.S. Food and Drug Administration has granted the company orphan drug designation for its enzyme replacement therapy in development to treat Lysosomal Acid Lipase Deficiency.
Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Oramed's Oral Insulin Capsules
July 7, 2010 8:35 am | by Bio-Medicine.Org | CommentsJERUSALEM, Israel , July 7, 2010 /- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, today announced that Oramed entered into a Manufacturing Supply Agreement (MSA) with sanofi-aventis. According to the MSA, sanofi-aventis will...
Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
July 7, 2010 8:35 am | by Bio-Medicine.Org | CommentsNEW YORK , July 7 /- Reportlinker.com announces that a new market research report is available in its catalogue: Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina http://www.reportlinker.com/p0186217/Stakeholder-Opinions-Vaccines-in...
Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity
July 7, 2010 8:34 am | by Bio-Medicine.Org | CommentsNEW YORK , July 7 /- Reportlinker.com announces that a new market research report is available in its catalogue: Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity http://www.reportlinker.com/p0...
Renhuang Begins Trading on NYSE Amex
July 7, 2010 8:34 am | by Bio-Medicine.Org | CommentsHARBIN, China , July 7 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (NYSE Amex: CBP ) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that,...
Ethicon, Inc. Expands Hemostasis Product Portfolio with Approval of the Company's First Synthetic Internal Use Sealant
July 7, 2010 8:33 am | by Bio-Medicine.Org | CommentsSOMERVILLE, N.J. , July 7 /- Ethicon, Inc., a worldwide leader in surgical care, announced today the introduction of ETHICON™ OMNEX™ Surgical Sealant, ETHICON™ Biosurgery's first synthetic sealant designed to achieve adjunctive hemostasis (stoppage of bleeding) in...
Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas
July 7, 2010 8:33 am | by Bio-Medicine.Org | CommentsCINCINNATI , July 7 /PRNewswire-USNewswire/ -- Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice – still an elusive goal when treating humans with cancer, according...
Genetically reprogrammed HSV given systemically shrinks distant sarcomas
July 7, 2010 7:37 am | by EurekAlert | Comments(Cincinnati Children's Hospital Medical Center) Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice -- still an elusive goal when treating humans with cancer,...
Researchers demystifying complex cellular communications hubs found in sensory neurons
July 7, 2010 7:37 am | by EurekAlert | Comments(American Society for Biochemistry and Molecular Biology) It's safe to say that cilia, the hairlike appendages jutting out from the smooth surfaces of most mammalian cells, have long been misunderstood -- underestimated, even.
Frontiers in Cardiovascular Biology: July 16-19, 2010, Berlin, Germany
July 7, 2010 7:37 am | by EurekAlert | Comments(European Society of Cardiology) Frontiers in Cardiovascular Biology, the first scientific meeting ever organized by the Council on Basic Cardiovascular Science of the European Society of Cardiology, is being held in Berlin this month to provide a new European platform for the...
